Drug Discovery World

JULY 5, 2023

The scientific community has 50 years of research fundamentals under their belts to make a substantial difference in patient care, particularly in the areas of immunotherapy and precision oncology. RA: What is the current state of the cancer research industry? We’re starting to see that this goal is realisable.

Research 98

Research Protein Scientist Immune Response 98

The Pharma Data

JANUARY 24, 2021

25, 2021 /PRNewswire/ — Notch Therapeutics Inc., Senior Vice President, Preclinical & Translational Sciences Chris Bond joins Notch with more than 18 years of experience working with biotechnology and pharmaceutical companies including Genentech, OncoMed, Juno Therapeutics, Celgene, and Kite. .

Engineer 52

Engineer Gene Editing Genome Genomics 52

The Pharma Data

APRIL 28, 2021

Department of Hematology, University Hospital of Nantes, France. This new therapeutic regimen has the potential to become a standard of care for patients with relapsed multiple myeloma , who now have another treatment option earlier in the progression of their disease.”. This EC approval closely follows the U.S.

Clinical Trials 40

Clinical Trials Clinical Trials Production Trials 40

The Pharma Data

MAY 27, 2022

Despite recent innovation, new therapeutic approaches are still needed,” said Maria-Victoria Mateos, M.D., Res), EMEA Therapeutic Area Lead Haematology, Janssen-Cilag Limited. 1 Findings presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting showed that at a median duration of 18 months follow-up (range, 1.5–30.5),

Antibody 52

Antibody Medicine Nurses Licensing 52

XTalks

AUGUST 2, 2023

In this in-depth article, we embark on a captivating journey to uncover the top 30 pharma and biotech companies that have been instrumental in shaping the future of medicine. With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

OCTOBER 1, 2020

Xtalks spoke with WeiQi Lin, MD, PhD, executive vice president, research & development, and principal scientist at DURECT Corporation — a company focused on developing drugs and drug delivery methods in therapeutic areas with significant unmet need — about her transition from academia to industry. Motivations for Transition.

Scientist 52

Scientist In-Vitro Research Life Science 52

The Pharma Data

JUNE 18, 2021

Professor of Medical Oncology at the Università Vita-Salute San Raffaele and CAPTIVATE steering committee member and investigator. vice president and global head of oncology development, AbbVie. vice president and global head of oncology development, AbbVie. NORTH CHICAGO, Ill. months of follow up.

Medicine 40

Medicine Production FDA Approval Trials 40